A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus

Trial Profile

A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Leiomyosarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2018 Planned primary completion date changed from 7 Jan 2018 to 7 Jan 2019.
    • 05 Jun 2017 Status changed from suspended to recruiting.
    • 25 Apr 2017 Results published in the Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top